Zacks Investment Research downgraded Syros Pharmaceuticals Inc (NASDAQ:SYRS) to Sell in a report released today.
- Updated: November 29, 2016
Yesterday Syros Pharmaceuticals Inc (NASDAQ:SYRS) traded -6.06% lower at $13.33. Syros Pharmaceuticals Inc’s 50-day average is $13.51 and its two hundred day average is $13.07. With the last stock price up 1.95% relative to the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.03% over the same period. Trade Volume was down over the average, with 18,326 shares of SYRS changing hands under the typical 39,330
Zacks Investment Research has downgraded Syros Pharmaceuticals Inc (NASDAQ:SYRS) to Sell in a report released on 11/29/2016.
Previously on Monday November 28, 2016, Cann reported on Syros Pharmaceuticals Inc (NASDAQ:SYRS) raised the target price from $0.00 to $28.00. At the time, this indicated a possible upside of 0.97%.
Recent Performance Chart
Syros Pharmaceuticals Inc has with a one year low of $8.16 and a one year high of $21.50 and has a market capitalization of $0.
General Company Details For Syros Pharmaceuticals Inc (NASDAQ:SYRS)
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing treatments for cancer and immune-mediated diseases. The Company's gene control platform focuses on identifying gene control targets linked to genomically defined patient populations, and drugging gene control targets. Its drug programs include SY-1425 and SY-1365. SY-1425 (tamibarotene) is an oral and selective agonist, or activator, of the transcription factor RARa. It is involved in advancing SY-1425 into genomically defined patient populations with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). SY-1365 is a selective small molecule inhibitor of cyclin-dependent kinase 7 (CDK7), a transcriptional kinase. SY-1425 is approved as tamibarotene in Japan for the treatment of acute promyelocytic leukemia (APL), a form of AML. It is developing SY-1365 with a focus on various indications, such as acute leukemia, Small cell lung cancer and Triple negative breast cancer.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.